Provided by Tiger Trade Technology Pte. Ltd.

Organogenesis Holdings Inc

3.95
+0.10502.73%
Volume:172.13K
Turnover:670.71K
Market Cap:500.67M
PE:-50.77
High:3.97
Open:3.81
Low:3.75
Close:3.84
52wk High:7.08
52wk Low:2.61
Shares:126.91M
Float Shares:55.47M
Volume Ratio:0.62
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0777
EPS(LYR):-0.0100
ROE:0.30%
ROA:0.18%
PB:1.96
PE(LYR):-394.50

Loading ...

Undervalued Opportunities: Penny Stocks To Watch In January 2026

Simply Wall St.
·
Jan 26

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%

Simply Wall St.
·
Jan 17

Organogenesis Holdings Price Target Maintained With a $9.00/Share by BTIG

Dow Jones
·
Dec 26, 2025

Organogenesis Begins FDA Rolling Review for ReNu Biologics License Application

Reuters
·
Dec 24, 2025

Organogenesis Holdings- to Complete Bla Submission With Final Modules Submitted in H1 2026

THOMSON REUTERS
·
Dec 24, 2025

Organogenesis Announces Initiation of Biologics License Application for Renu®

THOMSON REUTERS
·
Dec 24, 2025

Director Glenn H. Nussdorf Reports Disposal of Organogenesis Holdings Inc. Common Shares

Reuters
·
Dec 19, 2025

Organogenesis Plans to File Biologics Licenses Application for Knee Osteoarthritis Pain Therapy by 2025-End, Shares Up Pre-Bell

MT Newswires Live
·
Dec 16, 2025

Organogenesis Holdings Price Target Maintained With a $9.00/Share by BTIG

Dow Jones
·
Dec 16, 2025

Stocks to Watch: RCI Hospitality, Ready Capital, Organogenesis

Dow Jones
·
Dec 16, 2025

Organogenesis Confirmed to Start FDA License Application for ReNu

Dow Jones
·
Dec 16, 2025

Organogenesis to File BLA for ReNu After Positive FDA Meeting

Reuters
·
Dec 16, 2025

Organogenesis Holdings Inc - Submission Expected by End of 2025

THOMSON REUTERS
·
Dec 16, 2025

Organogenesis Announces Successful FDA Meeting and Plan to File Bla for Renu® for Knee Osteoarthritis Pain

THOMSON REUTERS
·
Dec 16, 2025

December 2025's Top Penny Stocks With Promising Potential

Simply Wall St.
·
Dec 16, 2025

Organogenesis Director and 10% Owner Glenn H. Nussdorf Reports Sale of Common Shares

Reuters
·
Nov 27, 2025

Organogenesis Holdings Is Maintained at Buy by BTIG

Dow Jones
·
Nov 20, 2025

Stock Track | Organogenesis Holdings Soars 22% on Stellar Q3 Earnings and Raised 2025 Outlook

Stock Track
·
Nov 07, 2025

Stock Track | Organogenesis Soars 10.54% After Hours on Strong Q3 Earnings and Raised 2025 Outlook

Stock Track
·
Nov 07, 2025

Regenerative medicine maker Organogenesis beats Q3 revenue estimates on rise in advanced wound care products

Reuters
·
Nov 07, 2025